TRML - NASDAQ

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%

HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.23B

EPS-2.8900

P/E Ratio-7.02

Earnings Date04/30/2026

trml

Total Non-Current Assets

Last Annual Value

40.16M

3-Year CAGR

102%

5-Year CAGR

104%

10-Year CAGR

43%

Adjust for Inflation

Tourmaline Bio, Inc. Competitors Analysis of Total Non-Current Assets

TRML · NASDAQ

Company	Total Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Tourmaline Bio, Inc. NASDAQ:TRML	40.16M	204.6%	52.3%	N/A
Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX	8.97M	-44.6%	68.4%	N/A
Dianthus Therapeutics, Inc. NASDAQ:DNTH	121.48M	296.2%	67.4%	72.9%
Enliven Therapeutics, Inc. NASDAQ:ELVN	1.29M	-39.1%	-13.5%	N/A
ORIC Pharmaceuticals, Inc. NASDAQ:ORIC	122.54M	42.8%	16.1%	N/A
Precigen, Inc. NASDAQ:PGEN	41.39M	-20.5%	-27.3%	-23.9%
Relay Therapeutics, Inc. NASDAQ:RLAY	43.05M	-16.5%	6.0%	N/A
Syndax Pharmaceuticals, Inc. NASDAQ:SNDX	1.62M	-63.0%	5.2%	12.4%
Terns Pharmaceuticals, Inc. NASDAQ:TERN	884.00K	-6.6%	-5.0%	N/A

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

HIDDEN

Intrinsic Value

Current Price: $47.98

Related Guides

Blog Categories

Continue your TRML research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.